Introduction
Eye drops are generally the preferred means to apply medication when treating ocular disorders; they are convenient and easy to use for most patients. However, this has difficulties despite the fact that the eye is easily accessible since effective drug delivery requires several barriers to be overcome. With aqueous formulations, delivering lipophilic or poorly water soluble drugs at an effective concentration is problematic as is blinking, tear washout and nasolacrimal drainage mechanisms. Up to 90% of the instilled dose is lost almost immediately; more is absorbed systemically to be eliminated by metabolic processes. It is estimated that <1% of the instilled dose penetrates into the eye.
1,2 When medication is introduced onto the eye there remains only a short time during which the drug can penetrate the cornea. 3 Corneal epithelium is a lipophilic structure with tight junctions at the superficial cell layers. This layer offers a resistant barrier which impedes penetration of drug molecules in aqueous solution.
However, the underlying stroma, which comprises ~90% of the cornea thickness has a hydrophilic gel-like structure and drugs in aqueous solution easily diffuse throughout this layer. 3, 4 Keratoconus is a debilitating condition of the cornea which can be treated using riboflavin to initiate ultraviolet 'A' induced collagen cross-linking. 5 This treatment has become routine practice for the treatment of keratoconus and other corneal disorders. [6] [7] [8] [9] However, the procedure relies on the physical removal of the epithelium under local anaesthesia to allow stromal penetration of riboflavin. 5 Developing a means to deliver riboflavin into the cornea without removal of the epithelium would be a significant improvement over the current procedure.
Compounds that are effective at extracting Ca 2+ ions have been reported to enhance ocular drug permeability. 10 Polyaminocarboxylic acids are a class of compound well known for Ca 2+ 4 sequestration [11] [12] [13] [14] and we have demonstrated this in a recent study using calcium chelators for improved ocular drug delivery. 15 Crown ethers are a class of synthetic macrocyclic polyether molecules first synthesized in the 1960's. 16 With their electron rich hydrophilic cavity due to the lone pairs associated with their oxygen atoms (where cation binding occurs), these molecules have a hydrophobic molecular ring structure, and are able to form guest-host complexes with metal ions and neutral organic molecules. It is thought that these ligands have better affinity to the metal cation on the basis of what fits in the inner cavity. The 'cavity-size' relationship was initially used as the underlying concept to explain binding strength and selectivity and suggested that the binding strength will be highest when the ionic diameter of a cation and the cavity of the crown ether are equal. 17 However, this principle has been revised with the most significant factors now considered to be pre-organisation and complementarity, solvation and chelate ring size. 18 The inherent flexibility of crown ethers allows them to adapt to a range of environments, displaying solubility in aqueous and lipophilic solvents and 'rapid, reversible ion binding characteristics'. 18 According to the Hansch lipophilicity scale, 18C6 has a value of zero, indicating a perfect hydrophilic / lipophilic balance. This is due to the ligand's ability to flex according to the medium it encounters, exposing either hydrophilic oxygen atoms or lipophilic ethylenic groups. 18 This is desirable for ocular drug delivery since the physiology of the eye means that a formulation has to traverse lipid and aqueous phases, and the relatively short residence time means enhancing permeation will allow for greater drug absorption.
Crown ethers have uses in many fields; chemistry, biology, industrial and pharmacological research. Their complexes are able to cross cellular membranes. [19] [20] [21] Crown ethers are used in other therapeutic areas, such as tumour treatment, 22 and they have been investigated for enhancement of drug delivery via vesicular formulations, 23, 24 but as far as we know they have not been investigated for ocular drug delivery. We hypothesized that if these compounds can form complexes with calcium ions they should be able to make the cornea more permeable to drugs by extracting Ca 2+ , thereby loosening epithelial tight junctions, and their ionophoric properties could assist transit of polyether/drug complexes across corneal epithelium.
In this study we investigated the effects of 3 cyclic polyethers of increasing ethylene oxide units, 12C4, 15C5 and 18C6 for their ability to bind and extract Ca 2+ and whether they afford any enhancement to the solubility of riboflavin and its corneal penetration. Isothermal titration calorimetry (ITC) was used to analyse their Ca 2+ binding properties and atomic absorption spectrometry (AAS) employed to determine their ability to extract Ca 2+ from corneal epithelium.
High performance liquid chromatography (HPLC) was employed to determine riboflavin solubility enhancement and in vitro experiments using Franz diffusion cells (FDC) to determine drug permeation through whole corneas. Bovine corneal opacity and permeability (BCOP) was used to determine toxicological implications from the use of crown ethers. In vivo experiments were performed in rats, but did not establish any statistically significant ocular permeability enhancement in live animals. 
Materials and Methods

Materials
Preparation of animal tissues
Fresh bovine eyes were sourced from a local abattoir (P C Turners, Farnborough, UK) and used within 24 hours after slaughter. Experiments to determine calcium extraction and corneal 8 opacity experiments employed whole eyes and excised corneas were used for in vitro permeability studies using Franz diffusion cells. All experiments were triplicated with a separate eye or cornea used for each repeat.
Whole eye experiments
We have previously reported an experimental technique that we developed to investigate corneal exposure to drug formulation ns, 28 the same protocol was employed in this investigation to determine Ca 2+ extraction from corneal epithelia. Briefly, individual eyes were placed in beakers, cornea uppermost and packed with loosely rolled up clingfilm to prevent movement, Franz diffusion cell donor compartments were placed over the cornea and held in place by wrapping the whole assembly with clingfilm ensuring a good seal on the eye, the beakers were placed in a water bath at 34 C. After 10 minutes equilibration the corneas were exposed to aqueous crown ether solutions at either 1 mg mL -1 or 30 mg mL -1 at pH 7.4 ± 0.2. After three hours exposure the solutions were recovered, centrifuged at 10000 rpm (10 g) for ten minutes. Aliquots of each supernatant were diluted by a factor of 100 in 0.25% aqueous LaCl3 solution for analysis by AAS.
Effect of crown ethers on riboflavin solubility
A series of aqueous crown ether solutions were prepared at 1, 10, 20 and 30 mg mL -1 for each molecular variant, 12C4, 15C5 and 18C6. To each solution an excess riboflavin was added at 1 mg mL -1 , and an aqueous solution of saturated riboflavin was used as a control. These solutions were kept in glass vials, wrapped in aluminium foil and stirred overnight at room temperature.
Riboflavin saturated solutions were filtered using 0.2 µm Minisart® syringe filters, then diluted with ultrapure water by a factor of 10 for HPLC analysis. Our previous studies have shown riboflavin to be photodegradable, 28 and this agrees with data reported by Terekhova et. al.
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therefore all experiments and samples were shielded from light using aluminium foil prior to analysis. The association constants of complexation for the crown ethers and riboflavin were calculated using Equation 1.
Where Ka:b is the association constant, S0 is the intrinsic aqueous solubility of riboflavin and slope is the gradient given by the equation of the graph for riboflavin solubility in crown ether solutions.
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Riboflavin solubility enhancement using crown ethers was calculated using Equation 2.
Where RFCrown(%) is crown ether enhanced riboflavin concentration, ∆RF is the difference between enhanced riboflavin concentration and the intrinsic aqueous concentration of riboflavin and RFwater is the intrinsic aqueous concentration of riboflavin.
Effect of crown ethers on riboflavin permeability
Solutions of 12C4, 15C5 and 18C6 crown ethers at concentration of 1 and 30 mg mL -1 in PBS, pH 7.4 ± 0.2 were prepared; riboflavin was added at 0.08 mg mL -1 to dissolve. A solution of riboflavin in PBS, pH 7.4 ± 0.2 was also prepared at the same concentration as a control.
Riboflavin permeability was measured using fresh bovine corneas fitted epithelium uppermost in standard Franz diffusion cells (FDC), each cell having an exposed area of cornea of 1.54 cm 2 .
16.5 mL of PBS was placed in the receiving chamber. Prepared FDCs were placed in a water bath, stirred at 34°C ± 1°C to mimic the physiological temperature at the corneal surface. 32,33 1 mL of aqueous crown ether solutions, and control was added to the donor compartments which were then covered to prevent evaporation. 0.4 mL aliquots were sampled every hour for 4 hours using sink conditions. Analysis by HPLC was carried out immediately after all samples had been collected to avoid drug degradation. Apparent permeability and steady-state flux were calculated using Equation 3.
Where Papp is the apparent permeability of riboflavin through bovine cornea, Q is total drug permeated at time t, ∆Q/∆t is the steady-state flux into the receiving solution (µmol min -1 ) which equates to the gradient of the linear portion of the graph, 60 is minutes to seconds conversion factor, A is the area of exposed cornea (1.54 cm 2 ) and Co is the initial amount of drug added to the donor chamber.
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Cornea extracts
Crown ether exposed corneas from the riboflavin permeability experiments were trimmed of scleral tissue, blotted dry and placed in vials containing 5 mL absolute ethanol to extract riboflavin. They were wrapped in foil, placed in a box and stored at room temperature for 3 days.
After extraction, 1 mL of the extraction solvent was centrifuged for 10 minutes at 10000 rpm (10 g) and the supernatant analysed by HPLC. After riboflavin extraction the corneas were placed in an oven at 40°C overnight to dry and their weight recorded to allow calculation of absorbed riboflavin per mg dry corneal tissue.
Toxicological investigation
Normal cornea's are transparent and impermeable to fluorescein dye due to tight junctions in the corneal epithelium. 34 Application of a substance which can denature proteins or cause corneal injury, leading to permeation of the fluorescein dye, reflects toxicological effects to the epithelium. Using a method established in the Bovine Cornea Opacity/Permeability Test 35 (BCOP) described in, 34 a scale of epithelial damage and fluorescent intensity was compiled.
Corneal opacity and permeability was evaluated using the BCOP test in order to explore toxicological characteristics of crown ethers in comparison to known penetration enhancers and irritants, i.e. benzalkonium chloride and sodium hydroxide. Fresh whole bovine eyes were placed in cups which were subsequently placed in 150 mL beakers, with the corneas facing uppermost. A few drops of PBS were applied to the corneal surface, the beaker was placed in a closed water bath at 34ºC ± 1ºC and allowed to equilibrate for 10 minutes. A silicon ring was placed on top of the cornea and 0.1 mL of various solutions was applied, including PBS, 18C6 1 and 30 mg mL -1 , 15C5 1 and 30 mL -1 , 12C4 30 mL -1 , EDTA 1 mg mL -1 , BAC 0.02%, BAC 0.1%, BAC 0.5%, BAC 1%, BAC 2% and NaOH 0.5M and 1M. The test solution was left on for 30 seconds before being washed off with 10 mL PBS. The beaker was then incubated for a further 10 minutes 34ºC ± 1ºC. The eye was then removed from the beaker and photographed with the silicon ring still in place using a Logitech webcam C920-C, images included in supporting information (Table S1 ). Then 0.1 mL of 2% w/v fluorescein dye solution was placed in the ring and left for 1 minute. The ring was removed and the dye was washed off with 10 mL PBS. The eye was observed under the fluorescence microscope and the fluorescence image was acquired with the exposure set to 130 ms, images included in supporting information (Table S2) .
Both sets of images were processed using ImageJ 1.50b software V 1.8.0_60. Each photograph was converted to 8-bit images, then the mean grey area function was used to measure opacity for the images, data included in supporting information, (Table S3) . Fluorescence image data shown in supporting information ( Table S4 ). The aim of this experiment was to assess any toxicity of crown ethers in comparison to known irritants, e.g. NaOH, and BAC 0.02% which is often used as a preservative and also as a penetration enhancer in ocular formulations.
In vivo experiments
All in vivo experiments reported in this work were approved by the Ethical committee of Kazan State Medical University (approval no 5 from 28 th May 2012). These experiments were conducted with 0.08 mg mL -1 riboflavin solutions with and without 30 mg mL -1 12C4. These experiments were performed in 3 months Wistar male rats weighting 200-250 g. Animals were housed in stainless steel cages and were fed with a standard multi-ration pellets for rodents (Effect Ltd, Chapaevsk, Russian Federation) and had unlimited access to water. Each formulation was tested in 3 animals. Each animal received 2 mL of the drug solution into both eyes, gradually instilled within 40 minutes. Then animals were sacrificed with a guillotine; both eyes were enucleated using scissors, weighed, quickly washed with 1 mL of 0.9 % saline solution and placed into 1 mL methanol for the drug extraction. Extraction was continued in a refrigerator at 4ºC for 24 hours; 0.2 mL of each extract was then mixed with 0.8 mL 0.1 % of aqueous orthophosphoric acid followed by HPLC analysis. Separate experiments were performed to evaluate the retention of sodium fluorescein solutions on corneal surface in rats (n=3). A single drop of 1 mg mL -1 sodium fluorescein solution (~0.05 mL) was administered on rat's cornea; UV light at 254 nm (VL-6.LC, Vilber Lourmat) was briefly shone into their eye to ensure the dye detection, which under these conditions showed green fluorescence, and digital images were taken immediately and 5 minutes after drop administration.
Histological studies
All histological experiments were conducted similarly to the experiments on in vivo administration of riboflavin described in the previous section. Following 40 minutes administration of 1 mL 0.08 mg mL -1 riboflavin solution with and without 30 mg mL -1 12C4
(n=3), rats were sacrificed with a guillotine; their eyes were enucleated and mounted in OCT and kept on dry ice. Cross-sectioning of each corneal segment was performed on a cryostat (Thermo Scientific Microm HM 525) and fixed on glass slides followed by application of 50−75 μL of 1.5 µg mL -1 DAPI to stain the cell nuclei. Cross sections of rat's cornea were examined using fluorescence microscopy (Olympus BX63); each image was taken using DAPI (blue, maximum λemission = 461 nm).
HPLC analysis for in vivo experiments
In order to improve the sensitivity of riboflavin detection in the eye extracts from in vivo experiments, a novel HPLC method was developed. HPLC analysis was conducted using a .
Statistical analysis
Minitab® statistical analysis software package, version 16.2.4 was used to analyse data acquired during these experiments using one-way analysis of variance (ANOVA) and paired t-tests.
Probability of P < 0.05 was considered significant and a minimum of triplicate experiments were used to determine this. Results are reported as the mean ± standard deviation.
Results and Discussion
Crown ether enhanced aqueous solubility of riboflavin
It was shown that 12C4 at 1 mg mL -1 offered a slight reduction in riboflavin solubility at 0.074 ± 0.003 mg mL Crown ether / riboflavin association constants Ka:b were calculated using Equation 1, and riboflavin solubility enhancement relative to its intrinsic aqueous solubility calculated using Equation 2. It should be noted that the phase solubility plots for riboflavin with 15C5 and 18C6
are not linear, which introduces some inaccuracy in determination of Ka:b compared to 12C4. At 1 mg mL -1 crown ether reduced riboflavin solubility by -9% using 12C4** and enhanced riboflavin solubility by 16% for 15C5** and 17% for 18C6** and at 30 mg mL -1 they enhanced riboflavin solubility by 36% for 12C4,** 46% for 15C5*** and 42% for 18C6.*** Table 1 lists the concentrations of riboflavin in the various crown ether solutions together with the corresponding association constants and riboflavin solubility enhancement as a percentage relative to riboflavin in deionised water. 15, 16, 39, 40 Riboflavin is too large to reside within the cavity of any of the crown ethers investigated in this study, 28 however partial complexation is possible and more likely with the larger molecular variants and this could reasonably explain the increasing solubility of riboflavin as larger crown ethers are used. Further studies of the nature of the complexation between crown ethers and riboflavin could potentially be conducted using other techniques, e.g. NMR spectroscopy, but this is outside of the scope of the present work.
Isothermal titration calorimetry analysis of crown ether / Ca 2+
ITC was used to determine Ca 2+ binding efficiency of 5 mM 12C4, 15C5 and 18C6 solutions at physiological pH 7.4. Figure 2 shows individual raw data and corresponding isotherms of the respective compounds titrated with CaCl2. Fitting of the isotherm curves is poorer for crown ethers in comparison with other chelating agent reported by us in a previous study, 15 evident by the lack of any distinct transition seen in the isotherms. 
Measured values of enthalpy (ΔH), stoichiometry (N), binding affinity (Kb) and entropy (ΔS)
from this analysis are shown in Table 2 There is a strong interest of researchers in the studies of complexation between crown ethers and various cations. [41] [42] [43] A number of studies has been published on the analysis of complexation thermodynamics in these systems. Many of these studies were conducted using organic solvents, which is not relevant to interactions in biological systems. There is also lack of studies of the complexation between crown ethers and calcium ions in aqueous media. Izatt et al 44 45 could be due to the difference in the calorimetric equipment and protocols used in both studies.
Ca 2+ extraction from bovine cornea using crown ethers
Crown ethers are known for their ability to sequester metal ions, the efficiency of this effect depends on many factors, for example, cavity size, enthalpy and pH. 39, 40 Smaller metal ions deform the chelate ring to make interactions stronger between the metal ion and oxygen atoms within the molecule, whilst larger ions reside close to but outside the cavity. 15 Here, the ability of 12C4, 15C5 and 18C6 crown ether solutions to extract Ca 2+ ions from bovine cornea was investigated using atomic absorption spectrometry. Using the 'whole eye method', 28 hours exposure to bovine cornea. * P < 0.05, ** P < 0.01, *** P < 0.001, one way ANOVA, n = 3.
Effect of crown ethers on permeability of riboflavin through bovine cornea
In vitro studies using Franz diffusion cells were carried out to investigate any permeability enhancement of riboflavin using crown ethers. The receiving chamber was filled with PBS at physiological pH (16.5 mL) and 1 mL of each crown ether solution in PBS incorporating 0.08 mg mL -1 riboflavin was added to the epithelial side of the cornea. 200 µL aliquots were taken for HPLC analysis every 60 minutes for 240 minutes. Experiments were carried out in triplicate and analysis was carried out at the time of sampling to prevent sample degradation. Results are reported as the mean ± standard deviation. Statistical analysis by ANOVA was applied and P values <0.05 were considered significant. Figure 4a shows the overlaid riboflavin permeability profiles for crown ethers at 1 mg mL -1 , Figure 4b shows the graphs for crown ethers at 30 mg mL -1 , error bars have not been included for clarity. The same profiles are shown individually with error bars in supporting information ( Figure S1 ). The results show that 12C4, 15C5 and 18C6 crown ethers at 1 mg mL -1 all afford a moderate enhancement in riboflavin permeability across bovine cornea to 22 ± 6, 19 ± 7 and 14 ± 4 ng mL -1 at 240 minutes respectively compared to riboflavin in PBS which is 8 ± 2 ng mL -1 , whilst at 30 mg mL -1 they offer a significant enhancement at 62 ± 23, 35±4 and 33 ± 7 ng mL -1 respectively. There is no significant difference in riboflavin permeability enhancement between the different crown ethers except for the difference between 12C4 and 18C6 at 30 mg mL -1 .
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Apparent permeability and steady state flux were calculated using Equation 3 and the results are given in Table 3 . 
Figure 4
Permeability profiles for riboflavin in crown ether / PBS solutions through bovine cornea. Crown ethers at 1 mg mL -1 (a), 30 mg mL -1 (b) * P < 0.05, ** P < 0.01, *** P < 0.001, one way ANOVA, n = 3.
Comparing riboflavin permeability enhancing performance between crown ethers and polyaminocarboxylic acids at the same concentration (1 mg mL -1 ) and with riboflavin concentration at 0.08 mg mL -1 it has been shown that crown ethers have superior permeability enhancing properties ( Table 4) . The smallest crown ether molecular variant offered the best performance. 
Effect of crown ethers on riboflavin penetration into bovine cornea
When treating corneal disorders such as keratoconus, it is essential that riboflavin is taken up by the stroma where UVA collagen cross-linking is facilitated. 5 Therefore, crown ether mediated riboflavin transport into the cornea was evaluated.
Corneas from the above diffusion studies were trimmed to exclude limbal and scleral tissue.
Riboflavin was extracted using absolute ethanol with subsequent analysis using HPLC. It was found that all the crown ethers investigated enhanced corneal absorption of riboflavin significantly greater than riboflavin in PBS alone. At 1 mg mL -1 there was an increasing concentration of riboflavin extract from the corneas; 0.470 ± 0.003 ng mg -1 for 12C4,*** 0.930 ± 0.145 ng mg -1 for 15C5*** and 1.450 ± 0.182 ng mg -1 for 18C6.** At 30 mg mL -1 there was a further increase in riboflavin extract, however the trend reversed with the highest concentration for 12C4 at 1.790 ± 0.245 ng mg -1 ***, reducing to 1.510 ± 0.164 ng mg -1 for 15C5*** and to 1.00 ± 0.1975 ng mg -1 for 18C6.*** Table 5 lists the amounts of riboflavin extracted from bovine corneas after exposure to PBS with and without crown ether after 4 hours exposure. * P < 0.05, ** P < 0.01, *** P < 0.001, one way ANOVA, n = 3.
Table 5
Riboflavin extracted from treated corneas after 4 hours exposure, ng mg -1 . 1.000 ± 0.198*** * P < 0.05, ** P < 0.01, *** P < 0.001, one way ANOVA, n = 3.
Crown ether solution in
Toxicological investigation
Epithelial damage is linked to corneal opacity and this phenomenon can be indicative of a substances ocular toxicity. Figure 5 shows that the three different crown ethers, 12C4, 15C5 and 18C6, produce a similar level of epithelial change, and increasing the concentration from 1 mg mL -1 to 30 mg mL -1 does not increase induced opacity. The level of epithelial damage caused by crown ethers was similar to that caused by the various concentrations of the BAC compounds and was much lower compared with the positive controls, NaOH 0.5 M and 1.0 M, which display a high level of corneal opacity due to alkali burning. BAC is often used in ocular formulations in concentrations up to 0.02% to act as a penetration enhancer and preservative. 47 At higher concentration BAC is known to be an irritant and toxic. No significant difference between all tested compounds except for the positive controls which showed a significantly damaging effect on bovine cornea epithelia.*** *** P < 0.001, one way ANOVA, n = 3.
Crown ethers display ionophoretic properties in cell membranes and behave similarly to natural ionophores, i.e. valinomycin, a cyclicdepsipeptide antibiotic. 22, 49 Therefore, their toxic effect is thought to be due to penetration of the cellular bilayer membrane. 50 By applying these compounds to the cornea, epithelial disruption allows for permeation of fluorescein dye. Figure   6 shows that the fluorescent intensity of epithelial surfaces treated with the crown ethers is comparable to corneas treated with BAC 1% and 2%.* High permeation of the fluorescein dye shows that if the permeability enhancer was to be used in conjunction with a therapeutic compound such as riboflavin in eye drop formulations, it would afford assisted transport into the cornea and could eliminate the need for invasive epithelial removal. Comparing crown ethers with BAC in the concentrations shown suggests they appear to be more toxic than BAC at the accepted level (0.02%)* used in many eye drop formulations, but less toxic than BAC concentrations >0.1% and EDTA at 1mg mL -1 , especially for the 12C4 variant. The positive controls 0.5 M NaOH and 1.0 M NaOH were significantly more toxic than all other compounds tested.*** * P < 0.05, ** P < 0.01, *** P < 0.001, one way ANOVA, n = 3. 
In vivo experiments
In vivo experiments were conducted in Wistar rats (n=3) to test ocular penetration of riboflavin using 0.08 mg mL -1 drug formulations with and without 30 mg mL -1 12C4, the crown ether that demonstrated the best penetration enhancement performance in vitro. 2 mL of the drug formulations were instilled into both eyes gradually within 40 min ( Figure S2 ). This timing was chosen to ensure the practicality of working with live animals and also to keep it relatively close to the drug administration procedure used clinically (30 min 5 Additional experiments were performed to evaluate the effect of riboflavin formulations with and without 30 mg mL -1 12C4 on the epithelial morphology of rat corneas. Figure 7 shows the histological images of rat corneas, following in vivo administration of 1 mL 0.08 mg mL 
Conclusions
Crown ethers were investigated for their riboflavin solubility enhancing properties which could improve the drugs bioavailability. It was found that 12C4 at 1 mg mL -1 offered a slight reduction to the solubility of riboflavin whilst 15C5 and 18C6 at 1 mg mL -1 and all the investigated crown ethers at higher concentrations offered significant enhancement to riboflavin solubility, thereby increasing its availability for use in ocular drug formulations. Permeability enhancement of bovine corneas was investigated based on crown ethers ability to sequester metal ions, namely Ca 2+ , and on their ionophoric properties which could potentially improve drug transport across the physical barriers of the cornea. Riboflavin transport through bovine cornea was enhanced by all the crown ethers investigated and it was found that 12C4 was the most efficient at both concentrations tested (1 mg mL -1 and 30 mg mL -1 ), this could be due the size differences of the crown ether / drug complex. Crown ethers in PBS were found to significantly improve Ca 2+ extraction from corneal epithelia compared to PBS alone; therefore they have the ability to 33 loosen Ca 2+ dependant tight junctions in the epithelial membrane. The permeability enhancing properties of crown ethers were shown to be superior compared to polyaminocarboxylic acids investigated in our previous study, 15 however, it is concluded that crown ethers ionophoric properties enhance riboflavin permeability more than their Ca 2+ sequestering properties. Further experiments determined that all the crown ether solutions investigated were efficient at delivering riboflavin into the corneal stroma and this is necessary for effective treatment following established UV 'A' induced collagen cross linking for the treatment of keratoconus and other conditions of the cornea. Crown ethers are novel compounds which have not previously been investigated for ocular drug delivery prior to this study, therefore an assessment of potential toxicological implications of using crown ethers in ocular formulations was carried out and their toxicity was found to be of a similar level to BAC which is used as a preservative and penetration enhancer for eye drop medication. Crown ethers at 1 mg mL -1 and 30 mg mL Further studies will be required to evaluate the potential of crown ethers to enhance corneal permeability for other drugs. Additionally, the studies where crown ethers are combined with mucoadhesive polymers to enhance drug permeation and to improve pre-corneal retention will be of interest. Our recent study of timolol maleate formulations 52 demonstrated that the combination of permeability enhancers with some mucoadhesive polymers could potentially inhibit drug permeation through the cornea despite the improvements in pre-corneal retention, which indicates that there is still lack of understanding of permeability enhancement effects in multicomponent drug formulations.
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